Drug
RG-4733 clinical trials
Also written RO4929097 and RG4733.
- studies test it
- 33
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
- R4733
- 16
Studies by the year they started
33 studies that test it; most in 2010 (30)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 30 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 15
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 31
National Cancer Institute (NCI) (31) · Hoffmann-La Roche (2)
Often tested with
Tested in the same studies.
Temozolomide (2) · Cisplatin (1) · Vinblastine (1) · Cediranib (1) · Capecitabine (1) · Temsirolimus (1) · Gemcitabine (1) · Bicalutamide (1)
Studies
Open first, then newest update. How each study uses RG-4733 is read from its arms, and is right about nine times in ten.
Testing it · 33
- RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT01217411Written as Gamma-Secretase Inhibitor RO4929097
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedPhase 1/2National Cancer Institute (NCI)NCT01196416Written as Gamma-Secretase Inhibitor RO4929097
- Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01200810Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
- RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnPhase 2National Cancer Institute (NCI)NCT01251172Written as Gamma-Secretase Inhibitor RO4929097
- RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell LeukemiaWithdrawnPhase 1National Cancer Institute (NCI)NCT01236586Written as RO4929097
- RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedPhase 2National Cancer Institute (NCI)NCT01175343Written as Gamma-Secretase Inhibitor RO4929097
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01151449Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
- Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal CancerWithdrawnPhase 2National Cancer Institute (NCI)NCT01270438Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
- A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) TherapyCompletedPhase 2National Cancer Institute (NCI)NCT01141569Written as Gamma-Secretase Inhibitor RO4929097
- An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung CancerCompletedPhase 2Hoffmann-La RocheNCT01070927Written as RO4929097
- A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.CompletedPhase 1Hoffmann-La RocheNCT00532090Written as RG4733
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedPhase 2National Cancer Institute (NCI)NCT01120275Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
- RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT01189240Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
- RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line ChemotherapyTerminatedPhase 2National Cancer Institute (NCI)NCT01193868Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
- RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedPhase 1National Cancer Institute (NCI)NCT01119599Written as Gamma-Secretase Inhibitor RO4929097
- RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedPhase 1National Cancer Institute (NCI)NCT01193881Written as Gamma-Secretase Inhibitor RO4929097
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast CancerTerminatedPhase 1National Cancer Institute (NCI)NCT01238133Written as Gamma-Secretase Inhibitor RO4929097
- RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerTerminatedPhase 1National Cancer Institute (NCI)NCT01149356Written as Gamma-Secretase Inhibitor RO4929097
- Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal CancerTerminatedPhase 1National Cancer Institute (NCI)NCT01198535Written as Gamma-Secretase Inhibitor RO4929097
- RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By SurgeryTerminatedPhase 1National Cancer Institute (NCI)NCT01071564Written as Gamma-Secretase Inhibitor RO4929097
See all 33 studies that test RG-4733 →
Given in every arm · 2 — RG-4733 is usual care beside what is tested
- Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedPhase 1/2National Cancer Institute (NCI)NCT01154452Written as Gamma-Secretase Inhibitor RO4929097
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedPhase 2National Cancer Institute (NCI)NCT01122901Written as gamma-secretase/Notch signalling pathway inhibitor RO4929097
Codes
What other systems call RG-4733 · ClinicalTrials.gg INT005523
- MeSH (NLM) C5451852,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KK8645V7LERG-4733Confirmed FDA, NLM, Wikidata
- Wikidata Q27088591RG-4733Confirmed FDA, NLM, Wikidata
- DrugBank DB11870One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545185 | 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KK8645V7LE | RG-4733 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088591 | RG-4733 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB11870 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.